主动权益基金多点开花 长城基金多只产品近一年业绩跻身同类前30%

Core Viewpoint - The A-share market has shown a strong performance in 2023, driven by themes such as AI technology, new consumption, and innovative pharmaceuticals, with notable achievements from Changcheng Fund's active equity funds [1] Group 1: Fund Performance - As of July 31, Changcheng Fund has 17 active equity funds ranked in the top 30% of their peers over the past year, showcasing diverse investment directions including innovative pharmaceuticals, new consumption, AI technology, robotics, military electronics, and Hong Kong stocks [1] - In the innovative pharmaceutical sector, funds managed by Tan Xiaobing have excelled, with three funds focusing on the healthcare industry ranking 10/1830, 5/83, and 19/83 in their respective categories over the past year [2] - The Changcheng Innovation-Driven fund, co-managed by Tan Xiaobing and Yang Weiwei, has focused on semiconductors, AI applications, and military sectors, achieving top rankings in their category [3] Group 2: Investment Strategies - Changcheng Fund emphasizes a top-down investment approach, with managers like You Guoliang optimizing their portfolios in AI computing and military sectors, resulting in strong performance rankings [4] - The fund's strategy includes a focus on overseas computing and semiconductor manufacturing, with managers like Shu Wenyu achieving commendable rankings in their respective categories [4] - The fund's diverse investment across various sectors, including military, AI, semiconductors, and new consumption, has led to several funds ranking in the top 30% of their peers [4] Group 3: Future Outlook - Changcheng Fund is committed to fundamental research and the development of a robust investment research system, aiming to enhance active management capabilities and create more value for investors in the future [4]